Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
Pfizer (PFE) announced on Wednesday that Elrexfio, a treatment for a type of blood cancer called multiple myeloma, reached the primary endpoint in a late-stage trial, raising prospects for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results